Heading to DUKPC 2024? Schedule time with Digostics and AgaMatrix!
We are excited to attend Diabetes UK Professional Conference 2024 with our new partners AgaMatrix. If you're looking for a better way to deliver diabetes screening, consider booking a meeting with Digostics and AgaMatrix in London!
Heading to DUKPC 2024? Schedule time with Digostics and AgaMatrix!
We are excited to attend Diabetes UK Professional Conference 2024 with our new partners AgaMatrix. If you're looking for a better way to deliver diabetes screening, consider booking a meeting with Digostics and AgaMatrix in London!
Revolutionising Diabetes Detection with Home Testing
Digostics' revolutionary new testing platforms offer the world's first and only alternative to in-clinic testing for glucose intolerance by enabling the oral glucose tolerance test (OGTT) to be performed at home.
Our platforms offer the same level of accuracy as clinic tests but without any of the staffing requirements, risks of sample degradation and laboratory delays that often impact clinic testing capacity.
By removing the need for in-clinic tests, we provide a gateway to more extensive testing, faster results and unparalleled opportunities for earlier clinical intervention.
Revolutionising Diabetes Detection with Home Testing
Digostics' revolutionary new testing platforms offer the world's first and only alternative to in-clinic testing for glucose intolerance by enabling the oral glucose tolerance test (OGTT) to be performed at home.
Our platforms offer the same level of accuracy as clinic tests but without any of the staffing requirements, risks of sample degradation and laboratory delays that often impact clinic testing capacity.
By removing the need for in-clinic tests, we provide a gateway to more extensive testing, faster results and unparalleled opportunities for earlier clinical intervention.
.png?width=200&height=49&name=GTT@home%20Logo%20-%20Digostics%20Orange%20(1).png "GTT@home Logo - Digostics Orange (1)"){kind=small}
The Future of Diabetes Testing, Today
Digostics uses advanced wireless and sensor technologies to enable safe and secure diabetes testing at home.
We ensure that a greater number of patients can be screened for diabetes without compromising test accuracy or adding to the burden of overworked clinical care teams.
GTT@home is Digostics' breakthrough solution and the world's first and only home OGTT, conveniently providing clinic-equivalent test results.
The Future of Diabetes Testing, Today
Digostics uses advanced wireless and sensor technologies to enable safe and secure diabetes testing at home.
We ensure that a greater number of patients can be screened for diabetes without compromising test accuracy or adding to the burden of overworked clinical care teams.
GTT@home is Digostics' breakthrough solution and the world's first and only home OGTT, conveniently providing clinic-equivalent test results.
Digostics and AgaMatrix Partner to Introduce Home OGTT for UK Expectant Mothers
Digostics and AgaMatrix have teamed up to revolutionise diabetes detection together. This partnership grants AgaMatrix exclusive distribution rights for GTT@home, leveraging their existing NHS relationships and expertise in GDM monitoring.
By simplifying GDM testing and offering a seamless experience for expectant mothers, Digostics and AgaMatrix aim to bridge the gap between GDM testing and post-diagnosis care, ultimately enhancing patient outcomes.
Digostics and AgaMatrix Partner to Introduce Home OGTT for UK Expectant Mothers
Digostics and AgaMatrix have teamed up to revolutionise diabetes detection together. This partnership grants AgaMatrix exclusive distribution rights for GTT@home, leveraging their existing NHS relationships and expertise in GDM monitoring.
By simplifying GDM testing and offering a seamless experience for expectant mothers, Digostics and AgaMatrix aim to bridge the gap between GDM testing and post-diagnosis care, ultimately enhancing patient outcomes.
Accurate OGTT Results from the Comfort of Home
Discover how GTT@home provides reliable results that match those obtained in a clinical setting by downloading the associated study.
"GTT@home has an excellent correlation and low bias compared to a reference glucose analyser, with an excellent agreement in categorisation of glucose tolerance."
Professor Steve Luzio, Swansea University
Book a Meeting at DUKPC 2024
To learn more about Digostics and GTT@home while at DUKPC, book a consultation with Digostics' CEO, James Jackson or Digostics' Chairman, Hugo Tewson.